Use of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
Authors:
- Bianca Caroline BenedictoBBBianca Caroline Benedicto
- Beatriz Taveira ConstantinouBCBeatriz Taveira Constantinou
- Amauri Moreira Leite JuniorAJAmauri Moreira Leite Junior
- Soraya Hussein OrraSOSoraya Hussein Orra
- Beatriz Sanches MolinaBMBeatriz Sanches Molina
- Tayná Pereira Leite de AlmeidaTATayná Pereira Leite de Almeida
- Beatriz Brandão da Silva NavasBNBeatriz Brandão da Silva Navas
- Rodrigo Afonso da Silva SardenbergRSRodrigo Afonso da Silva Sardenberg
- Fernando Gonçalves de AlmeidaFAFernando Gonçalves de Almeida
- Ronaldo Soares MaiaRMRonaldo Soares Maia
- José Arnaldo Shiomi da CruzJCJosé Arnaldo Shiomi da Cruz
Open Access
- 1 January 2026
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 41
Abstract
Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.Keywords
This publication has 21 references indexed in Scilit:
- Guidelines for Meta-analyses and Systematic Reviews in UrologyEuropean Urology, 2025
- A Prospective, Observational Study of Use Combination Silodosin 8 mg Plus Serenoa Repens, Urtica Dioica, Cucurbita Pepo (Rotaprost) Compared With Silodosin 8 mg Alone in Treatment Patients with Benign Prostate HyperplasiaClinical Complementary Medicine and Pharmacology, 2022
- Erectile Dysfunction and Lower Urinary Tract SymptomsEuropean Urology Focus, 2017
- A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: A herbal medicine preparation for the management of symptoms of benign prostatic hypertrophyComplementary Therapies in Medicine, 2013
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH)European Urology, 2005
- Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten MiktionsbeschwerdenDer Urologe B, 2000
- Saw Palmetto Extracts for Treatment of Benign Prostatic HyperplasiaJAMA, 1998
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- The zonal anatomy of the prostateThe Prostate, 1981